Bluejay Diagnostics EPS BJDX
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$34.72
- Latest quarter, Q2 FY26
- −$4.48
- Fiscal year 2025
- −$98.84
Bluejay Diagnostics' earnings per share was −$34.72 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$4.48.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$98.84 | n/a |
| FY2024 | −$11689.44 | n/a |
| FY2023 | −$58776.00 | n/a |
| FY2022 | −$59008.00 | n/a |
| FY2021 | −$52480.00 | n/a |
| FY2020 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$4.48 | n/a | −$34.72 | |
| Q1 FY26 | −$7.80 | n/a | −$52.80 | |
| Q4 FY25 | −$6.28 | n/a | −$98.84 | |
| Q3 FY25 | −$16.16 | n/a | −$136.24 | |
| Q2 FY25 | −$22.56 | n/a | −$1351.12 | |
| Q1 FY25 | −$53.84 | n/a | −$5427.12 | |
| Q4 FY24 | −$43.68 | n/a | −$11689.44 | |
| Q3 FY24 | −$1231.04 | n/a | −$23549.76 | |
| Q2 FY24 | −$4098.56 | n/a | −$35654.72 | |
| Q1 FY24 | −$6316.16 | n/a | −$49156.16 | |
| Q4 FY23 | −$11904.00 | n/a | −$58776.00 | |
| Q3 FY23 | −$13336.00 | n/a | −$61976.00 |
Against its peers
Companies in Medical - Instruments & Supplies nearest Bluejay Diagnostics' size, closest first, today.
| Company | EPS, 12 months |
|---|---|
| BJDXBluejay Diagnostics | −$34.72 |
| VJETFlyte Aviation | n/m |
| PFSAProfusa | n/m |
| IVFINVO Fertility | n/m |
| BBLGBone Biologics | −$1.41 |
| TNONTenon Medical | −$25.65 |
| AMIXAutonomix Medical | n/m |
| NXGLNexgel | −$14.20 |
| ADGMAdagio Medical | −$1.43 |
| GCTKGlucotrack | n/m |
| XAIRBeyond Air | −$68.40 |
| Peer median | −$14.20 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Bluejay Diagnostics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.